Since Hanahan and Weinberg published their breakthrough paper outlining six hallmarks of cancer in 2000, the progression of understanding cancer cell biology has been significant1. Since then, advances in subjects like immune modulation and tumor microenvironment have resulted in revision and an update of these hallmarks. This has occurred not once, but twice2,3, with the most recent review identifying the following:
- Selective proliferative advantage
- Altered stress response
- Vascularization
- Invasion and metastasis
- Metabolic rewiring
- Immune modulation
- An abetting microenvironment
With continuous evolution of research in tumor biology, novel ideas have been developed about the behavior of several cancers, in addition to offering novel pharmacological targets and therapy techniques. A large amount of this progress has been developed through technological advancement, allowing studies that were previously unachievable, to be completed.
Particularly in the last decade, there have been significant advances made in the area of in vitro translational models and live-cell assays, via both traditional 2D and advanced 3D cell culture systems. The development of purpose-built live-cell analysis instruments, like the IncuCyte® system (Essen BioScience), has transformed the field, enabling observation and quantification abilities of cancer cell biology over time, in an entirely non-perturbing way.
This white paper investigates some of the current research ideas across the seven hallmarks of cancer, and highlights the contribution of live-cell analysis for the elucidation of the biological mechanisms supporting these behaviors.
About Sartorius
Sartorius is a leading international pharmaceutical and laboratory equipment supplier. With our innovative products and services, we are helping our customers across the entire globe to implement their complex and quality-critical biomanufacturing and laboratory processes reliably and economically.
The Group companies are united under the roof of Sartorius AG, which is listed on the Frankfurt Stock Exchange and holds the majority stake in Sartorius Stedim Biotech S.A. Quoted on the Paris Stock Exchange, this subgroup is comprised mainly of the Bioprocess Solutions Division.
Innovative Technologies Enable Medical Progress
A growing number of medications are biopharmaceuticals. These are produced using living cells in complex, lengthy and expensive procedures. The Bioprocess Solutions Division provides the essential products and technologies to accomplish this.
In fact, Sartorius has been pioneering and setting the standards for single-use products that are currently used throughout all biopharmaceutical manufacturing processes.
Making Lab Life Easier
Lab work is complex and demanding: Despite repetitive analytical routines, lab staff must perform each step in a highly concentrated and careful way for accurate results.
The Lab Products and Services Division helps lab personnel excel because its products, such as laboratory balances, pipettes and lab consumables, minimize human error, simplify workflows and reduce physical workloads
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.